

Results of Retail Entitlement Offer

Not for release to US wire services or distribution in the United States

Key Highlights

- Microba has completed the Retail Entitlement Offer.
- Approximately A\$999,635 (before transaction costs) was raised in the Retail Entitlement Offer. The shortfall of \$6,723,832 will be placed under the underwriting and sub-underwriting arrangements with existing and new institutional shareholders, existing long term shareholders and high net worth investors.
- Funds raised under the Entitlement Offer will be used by Microba to fund the acquisition of UK based Invivo Clinical Limited (**Acquisition**) which was announced on Thursday, 19 October 2023.

Microba Life Sciences Limited (ASX:MAP) ("**Microba**" or "**the Company**") on 19 October 2023, announced the launch of a A\$20.0 million pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of new fully paid ordinary shares (**Entitlement Offer Shares**) at an offer price of A\$0.23 per Entitlement Offer Share (**Offer Price**).

The Entitlement Offer is comprised of a fully underwritten offer of 1 Entitlement Offer Share for every 4 shares to raise gross proceeds of A\$20.0 million.

Following the successful completion of the institutional component of its Entitlement Offer (**Institutional Entitlement Offer**), Microba is pleased to advise the results of the retail component of its Entitlement Offer (**Retail Entitlement Offer**).

The fully underwritten Retail Entitlement Offer of approximately A\$7.7 million raises the balance of the Entitlement Offer. The Retail Entitlement Offer is fully underwritten by Bell Potter Securities Limited and Morgans Corporate Limited (**Underwriters**, or the **Joint Lead Managers**).

Under the Retail Entitlement Offer, eligible retail shareholders with a registered address in Australia or New Zealand as at 7.00pm (Sydney time) on Monday, 23 October 2023 (**Record Date**), not being US persons or acting for the account or benefit of persons in the US (**Eligible Retail Shareholders**) were invited to participate in the Retail Entitlement Offer at the same Offer Price and offer ratio as the Institutional Entitlement Offer.

The Retail Entitlement Offer opened at 9.00am (Sydney time) on Thursday, 26 October 2023 and closed at 5.00pm (Sydney time) Thursday, 16 November 2023.

In addition to each Eligible Retail Shareholder's Entitlement under the Retail Entitlement Offer, Eligible Retail Shareholders were offered the opportunity to apply for additional New Shares under a "top-up" facility (**Oversubscription Facility**). Under the Oversubscription Facility, Eligible Retail Shareholders could apply for New Shares in excess of their Entitlement (**Additional Shares**) which represented the lower of that number which represented 100% of their Entitlement or \$50,000 worth of New Shares (**Additional Share Cap**).

The Retail Entitlement Offer was subscribed as follows:

Acceptances by Eligible Retail Shareholders	3,747,634 New Shares
Acceptances by Eligible Retail Shareholders under the Oversubscription Facility	598,605 New Shares
Shortfall	29,234,053 New Shares

The shortfall will be placed in accordance with the underwriting and sub-underwriting arrangements as detailed in the Retail Offer Booklet released to the ASX on 26 October 2023.

New Shares to be issued under the Retail Offer will rank equally in all respects with existing fully paid ordinary shares.

Settlement of the Retail Entitlement Offer is scheduled to occur on Wednesday, 22 November 2023, with New Shares expected to be allotted on Thursday, 23 November 2023, and trading to commence on a normal settlement basis on the Australian Securities Exchange (ASX) on the following day.

Indicative Entitlement Offer timetable

Event	Time and Date
Retail Entitlement Offer closed	5.00pm (Sydney time) Thursday, 16 November 2023
Results of the Retail Entitlement Offer announced to ASX	Monday, 20 November 2023
Settlement of Retail Entitlement Offer	Wednesday, 22 November 2023
Allotment of Entitlement Offer Shares issued under the Retail Entitlement Offer	Thursday, 23 November 2023
Normal trading of Entitlement Offer Shares issued under the Retail Entitlement Offer	Friday, 24 November 2023
Holding statements for Entitlement Offer Shares issued under the Retail Entitlement Offer dispatched	Friday, 24 November 2023
Annual General Meeting	Thursday, 30 November 2023
Completion of the Acquisition	Tuesday, 5 December 2023

This timetable is indicative only and may be subject to change without notice to, or consultation with, you. Microba reserves the right to amend any or all of these dates and times subject to the Corporations Act, the ASX Listing Rules and other applicable laws.

This announcement has been authorised for release by the Chair and CEO.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer
E: Luke.Reid@microba.com

Investor / Media Relations

E: investor@microba.com
W: <https://ir.microba.com/>
[Join our Investor Mailing List](#)

About Invivo Clinical Limited

Invivo Clinical Limited is a leading UK microbiome company which provides solutions to healthcare professionals and their patients. Invivo was established in 2007 and is headquartered in Stroud, Gloucestershire. The company has a product portfolio spanning Gastrointestinal, Vaginal, Oral and Urinary microbiome testing, together with a targeted set of evidence-based intervention formulations. With an active customer base of over 1,700 integrative healthcare practitioners Invivo prides itself on providing world-class microbiome solutions to improve patient outcomes.

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the

Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com

microbiome, health and disease for the development of new health solutions.

Disclaimer

Forward looking statements

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Microba, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Microba's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Not an offer in the United States

This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.